



Euro Forums

European Forum

Thurs. 07 Sept.

**Hilton Danube
Waterfront Hotel
Vienna**

follow us on



@OphthalmologyFF #OFF2023

European Programme



We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated portfolio of contact lenses, lens care solutions, and pharmaceutical and over-the-counter eye drops. Alcon is also at the forefront of innovation, partnering with Eye Care Professionals to bring the gift of sight to more people around the world.

That's been our legacy for more than 75 years—and continues to guide our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!



Welcome: EUROPEAN FORUM 2023

Welcome to Ophthalmology Futures 2023

We are pleased to welcome you to our 12th Annual European Forum to be held for the second time in Vienna, Austria. Once again, this in-person event will bring together leading innovators, practitioners, corporate leaders and investors. We are delighted that over 30 companies will be presenting updates regarding their journeys to bring forth medical products to address unmet needs in the treatment of vision threatening diseases. The ophthalmology innovation ecosystem is indeed robust as evidenced by a record number of companies submitting applications to present in 2023.

One of our fundamental goals is to make each Ophthalmology Futures meeting unique. This year, an all-star cast of ophthalmology leaders has been assembled to pay tribute to Gavin Herbert, a true pioneer in the advancement of therapies for eye disease. Panel topics include advances in cell and gene therapy for the anterior segment, novel drug discovery approaches, myopia in the digital age as well as advances in refractive surgery. A diverse panel of innovators and practitioners will debate which cataract surgical approach and IOL implantation is the best today. As in prior years, we will discuss investment in ophthalmology and global regulatory challenges and opportunities.

We are confident that you will enjoy the formal program as well as the networking opportunities that come with an in-person event. In recognizing that the world has forever changed with regard to travel as a result of a global pandemic, our program will also have a virtual component and be made available to those who are unable to make the trip to Vienna.

Ophthalmology Futures Forums would like to thank our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to keep registration costs low for all attendees!

Thank you for joining us in Vienna!

Keith Barton & Kuldev Singh
on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.
Registered in England No: 8125858.

Stellest®

Essilor®
#1 in spectacle lenses
worldwide*

EssilorLuxottica is proud to support the **Ophthalmology Futures Forums 2023**.

Join the panel on "Myopia in the digital age: is technology the answer?"
<https://www.opthalmology-futures.com/euro-2023/>

📅 **Thursday, 7 September,**
13:55 - 14:30 CET

*Euromonitor, Eyewear, 2023 edition; Essilor International company; worldwide retail value sales of RSP; [essilorluxottica.com](https://www.essilorluxottica.com)



Helping Doctors Improve Their Patients' Quality of Life.

ZEISS Medical Technology Business Group



Seeing beyond

Improving Quality of Life

ZEISS Medical Technology is proud to support the **Ophthalmology Futures European Forum**.

www.zeiss.com



In the relentless pursuit of
treatments for retinal diseases,

APELLIS IS LIGHTING THE WAY FORWARD

Our journey starts with
geographic atrophy (GA)

GA is an advanced form of age-related macular degeneration that leads to progressive and irreversible vision loss, substantially impacting patient quality of life.¹⁻³

It represents the most significant unmet medical need in ophthalmology given there are currently no approved treatments available.⁴

OUR SEARCH FOR SOLUTIONS
KNOWS **NO LIMITS** BECAUSE THESE
PATIENTS DESERVE NOTHING LESS

Visit **apellis-amd.eu** to learn
more about Apellis and our journey
in geographic atrophy



Apellis

References: 1. Gehrs KM, et al. *Ann Med* 2006;38(7):450-471. 2. Fleckenstein M, et al. *Ophthalmology* 2018;125(3):369-390. 3. Patel PJ, et al. *Clin Ophthalmol* 2020;14:15-28. 4. Riquet D (n.d.). European Parliament. Available at: https://www.europarl.europa.eu/doceo/document/P-9-2022-000876_EN.html (accessed January 2023).

Speakers:

PRESENTING COMPANIES

PANELLISTS & CHAIRS

CHAIRS & PANELLISTS

A

- **Ike Ahmed**
Ophthalmologist,
Prism Eye Institute
- **Marcus Ang**
Senior Consultant Ophthalmologist,
Singapore National Eye Centre
- **Laurent Attias**
Senior Vice President,
Head of Corporate Strategy, BD&L
and M&A, Alcon
- **Gerd Auffarth**
MD, Ruprecht-Karls
University of Heidelberg

B

- **Jeannette Bankes**
President & GM Surgical, Alcon
- **Scott Barnes**
Chief Medical Officer,
Staar Surgical
- **Keith Barton**
Co-Chair, Ophthalmology
Futures Forums

C

- **Chris Calcaterra**
EVP, Global Commercial Operations,
Glaukos
- **Mary Cantu**
Vice President,
Sight Sciences, Inc
- **Tara Capalbo**
General Manager, Abbvie
- **Francesco Carones**
Co-Founder & Medical Director,
Carones Ophthalmology Center
- **Rafael Chan**
Vice President, Implantables, Alcon
- **Dina Chaya**
Partner, Orbimed Healthcare Fund
Management
- **Andrew Chang**
Global Head of Sales Ophthalmic
Device & President of CZMI, ZEISS
- **Arthur Cummings**
Consultant Ophthalmologist,
Wellington Eye Clinic

D

- **Annegret Dahlmann-Noor**
Consultant Ophthalmologist,
Moorfields Eye Hospital
- **Laura de Benito-Llopis**
Consultant Eye Surgeon,
Moorfields Eye Hospital
- **Sheraz Daya**
Medical Director, Centre For Sight
- **Mor Dickman**
Doctor, University Eye Clinic
Maastricht
- **Kendall Donaldson**
Professor of Clinical Ophthalmology,
Bascom Palmer Eye Institute

E

- **David Endicott**
CEO, Alcon

F

- **Nahum Ferera**
CEO & Co-Founder, EyeYon Medical
- **Ian Flitcroft**
Consultant Paediatric
Ophthalmologist, Children's
University Hospital, Dublin

G

- **Stefano Gandolfi**
Professor & Chair,
University of Parma
- **Michael Giaquinto**
Senior Managing Director,
Leerink Partners
- **Andrzej Grzybowski**
Professor of Ophthalmology,
University of Warmia & Mazury

H

- **Ranya Habash**
Assistant Professor,
Bascom Palmer Eye Institute
- **Gavin Herbert**
Co-Founder, Allergan
- **Cameron Hudson**
SVP, Commercial OUS,
ELIOS Vision

K

- **Karsten Klabe**
Head Surgeon,
Breyer - Kaymak - Klabe

- **Aylin Kilic**
Associate Professor,
Swiss Vision Group
- **Viridiana Kocaba**
Director of Innovation & Senior
Clinician Scientist, Netherlands
Institute For Innovative Ocular
Surgery
- **Greg Kunst**
CEO, Aurion Biotech

L

- **Seba Leoni**
General Manager, Global Head,
Alcon Vision Suite
- **William Link**
Managing Partner,
Versant Ventures
- **Elizabeth Lumb**
Global Director Professional Affairs
Myopia, CooperVision

M

- **Scott MacRae**
Ophthalmologist, University
of Rochester Medical Center
- **Jim Mazzo**
Executive Chairman,
Neurotech Pharmaceuticals, Inc.
- **Peter McDonnell**
Director, Wilmer Eye Institute
- **Erik Mertens**
MD, Medipolis
- **Magda Michna**
Chief Clinical, Regulatory
& Medical Affairs Officer,
Staar Surgical
- **Michael Mrochen**
President, Allotex, Inc.
- **Dirk Muehlhoff**
Head of Refractive Lasers,
Carl Zeiss Meditec AG

P

- **Graziella Pellegrini**
Head of Cell Therapy Program,
University of Modena
& Reggio Emilia
- **Patricia Piers**
Director R&D, Johnson &
Johnson Vision
- **Matteo Pliovella**
Founder & Director,
Piovella Global Center
for Ophthalmology

- **Olga Prenat**
Head of Medical Marketing
and Professional Relations,
Essilor Luxottica

S

- **Ehsan Sadri**
Founder & CEO,
Visionary Eye Institute
- **Omar Sadruddin**
Vice President, Glaukos
- **Dirk Sauer**
Independent Board Chair
- **Frank Seitzinger**
Head of Business Sector, ZEISS
- **Kuldev Singh**
Co-Chair, Ophthalmology
Futures Forums
- **Jodbhir Singh Mehta**
Professor, Singapore National
Eye Centre
- **David Smadja**
Director of Refractive Surgery,
Hadassah Medical Center
- **Katya Smirnyagina**
Senior Partner,
Oxford Science Enterprises
- **Xiao-Yu Song**
Global Head of Research
& Development, Johnson &
Johnson Vision
- **Ingeborg Stalmans**
Head of the Glaucoma Clinic
UZ Leuven, Head of the Research
Group of Ophthalmology KU Leuven

T

- **Vance Thompson**
MD, Vance Thompson Vision
- **Sally Tucker**
Director, Emblem Consultancy

V

- **Michel Vanbrabant**
CEO, iStar Medical
- **Kristof Vandekerckhove**
Founder & Medical Director,
Alpina Eye Clinic

W

- **Limin Wang**
Regional Manager, Filtens Ltd.

Y

- **Elizabeth Yeu**
MD, Virginia Eye Consultants

PRESENTING COMPANIES

A

- **Atia Vision**
Dee Stephenson,
MD, President
- **Aurion Biotech**
Greg Kunst,
Vice President

B

- **Biophta**
Jean Garrec,
Founder & CEO

C

- **Ciliatech**
Olivier Benoit,
CEO
- **CustomLens AI**
Milind Pande,
Founder & CEO

D

- **Dopavision**
Mark Wuttke,
Associate Director, Scientific
Communications

E

- **ELIOS Vision**
Cameron Hudson,
Head of Marketing, OUS
- **Epion Therapeutics, Inc.**
Michael Webb,
CEO
- **Eximore Ltd.**
Eyal Sheerit,
CEO
- **EYE-GO A/S**
Henrik Nagel,
Business Development Director
- **EyeYon Medical**
Nahum Ferera,
CEO & Co-Founder

F

- **Filtens**
Limin Wang,
Regional Manager

G

- **Glaukos**
Tomas Navratil,
CDO

I

- **Implandata Ophthalmic Products**
Max Ostermeier,
CEO
- **iStar Medical**
David Stocker,
Marketing Coordinator

K

- **Kuria Therapeutics**
Keith Ward,
CEO

L

- **LensGen, Inc.**
Ramgopal Rao,
COO
- **LEP Biomedical**
Alan Hibbitts,
CEO

M

- **m-lab GmbH**
Dominik Beck,
Medical Device Executive
- **MachineMD**
Carsten Laue,
Chairperson
- **Mikajaki**
Michael Assouline,
President
- **Myra Vision, Inc.**
Robert Chang,
President & CEO

N

- **NovaSight Ltd.**
Ran Yam,
Marketing Manager

O

- **Oculus**
Riad Sherif,
VP Strategic Marketing & BD&L
- **Ophthalmic Therapeutic Innovation**
Tina Guanting Qiu,
President, CMO, CSO
- **Orasis Pharmaceuticals**
Elad Keda,
Sr. VP Strategy & Marketing

P

- **Photon Therapeutics**
Sunil Shah,
Director

S

- **Sanoculis**
Nir Israeli,
CEO

T

- **Tarsier Pharma**
Daphne Haim-Langford,
CEO & Chairperson
- **Twenty Twenty Therapeutics**
Dimitri Azar,
President & CEO

V

- **Vialase**
Pete England,
VP, Global Marketing

Timings:

EUROPEAN HYBRID FORUM

TIMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME

7:00 - 7:50
Registration & Refreshments

7:50 - 8:00
Welcome

- Keith Barton & Kuldev Singh

8:00 - 8:10
Market Overview

- Michael Giaquinto

8:10 - 8:50
Panel 1: Will Novel Glaucoma Drug Delivery Be Competitive Or Synergistic With MIGS?
CO-CHAIRS

- Keith Barton & Ingeborg Stalmans

PANEL

- Cameron Hudson
- Karsten Klabe
- Mary Cantu
- Michel Vanbrabant
- Omar Sardruddin
- Rafael Chan
- Stefano Gandolfi
- Tara Capalbo

8:50 - 10:15
Company Presentations 1

- Glaukos
- Elios Vision
- ViaLase
- Implandata Ophthalmic Products
- iSTAR Medical
- Ciliatech
- Sanoculis
- Myra Vision, Inc.
- LEP Biomedical
- Eximore Ltd.

10:15 - 10:40
Networking Break

10:40 - 11:10
Panel 2: Cell And Gene Therapy For The Anterior Segment & Other New Technology - Progress?
CO-CHAIRS

- Jodbhir Singh Mehta & Viridiana Kocaba

PANEL

- Greg Kunst
- Laura de Benito Llopis
- Marcus Ang
- Mor Dickman
- Nahum Ferera

11:10 - 12:30
Company Presentations 2

- Aurion Biotech
- EyeYon Medical
- Kuria Therapeutics
- Epion Therapeutics, Inc.
- Biophta
- EYE-GO
- Ophthalmic Therapeutic Innovation
- Oculus
- Orasis Pharmaceuticals
- Photon Therapeutics

12:30 - 13:15
Networking Lunch

13:15 - 13:55
Panel 3: Has Cornea-based Refractive Surgery Peaked?
CO-CHAIRS

- Arthur Cummings & Sheraz Daya

PANEL

- Aylin Kilic
- David Smadja
- Dirk Muehlhoff
- Erik Mertens
- Francesco Carones
- Scott Barnes
- Scott Macrae

13:55 - 14:30
Panel 4: Myopia In The Digital Age: Is Technology The Answer?
CO-CHAIRS

- Ian Flitcroft & Marcus Ang

PANEL

- Andrzej Grzybowski
- Andrew Chang
- Annegret Dahlmann-Noor
- Dirk Sauer
- Elizabeth Lumb
- Olga Prenat
- Xiao Yu Song

14:30 - 15:30
Company Presentations 3

- Dopavision
- NovaSight Ltd.
- Fitlens
- Tarsier Pharma
- MachineMD
- MIKAJAKI
- Twenty Twenty Therapeutics

15:30 - 16:00
Panel 5: How Has The Investment Environment Changed In The Last 2 Years?
CHAIR

- Katya Smirnyagina

PANEL

- Dina Chaya
- Ehsan Sadri
- Laurent Attias
- Limin Wang
- Michael Giaquinto
- Ranya Habash
- William Link

16:00 - 16:25
Networking Break

16:25 - 17:10
Panel 6: Leadership In Ophthalmology: Lessons From A Pioneer & His Disciples
CHAIR

- Jim Mazzo

INTERVIEWS

- Gavin Herbert

FOLLOWED BY A PANEL DISCUSSION

- Chris Calcaterra
- David Endicott
- Kuldev Singh
- Peter McDonnell

17:10 - 18:00
Company Presentations 4

- m-lab GmbH
- LensGen, Inc.
- CustomLens AI
- Atia Vision

18:00 - 18:40
Panel 7: Which Phaco & IOL Would I Want Today?
CO-CHAIRS

- Elizabeth Yeu & Gerd Auffarth

PANEL

- Frank Seitzinger
- Ike Ahmed
- Kendall Donaldson
- Kristof Vandekerckhove
- Matteo Piovella
- Patricia Piers
- Seba Leoni
- Vance Thompson

18:40 - 19:10
Panel 8: The Impact Of Global Harmonisation Of Regulatory Process On Medtech Innovation In Ophthalmology
CHAIR

- Kuldev Singh

PANEL

- Jeannette Bankes
- Magda Michna
- Michael Mrochen
- Sally Tucker
- Jan Willem De Cler

19:10 - 19:15
Summary & Concluding Comments From The Co-Chairs

- Keith Barton & Kuldev Singh

19:15 - 20:30
Cocktail Reception
Sponsored by:


FORUM SPONSORS

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND VIRTUAL REGISTRATION IS COMPLIMENTARY FOR EVERYONE

PLATINUM



At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years – and as the new Alcon, it's what guides our focus towards the brilliant future ahead.



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL," which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries.

To learn more about the ICL go to: www.discovericl.com.

GOLD



Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body's immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.



An Astellas Company

Iveric Bio, An Astellas Company, is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients' lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

SILVER



With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.

www.zeiss.com



At Janssen, we are translating our understanding of the biology of underlying retinal diseases to develop needed therapies that preserve and enhance vision. Janssen's clinical-stage retinal portfolio includes leading product candidates for inherited retinal diseases XLRP and achromatopsia.

Janssen is also expanding into more common eye diseases, including age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.



EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. Formed in 2018, its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. The Company brings together the complementary expertise of two industry pioneers, one in advanced lens technology and the other in the craftsmanship of iconic eyewear, to set new industry standards for vision care and the consumer experience around it. Influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux and Transitions, and world-class retail brands including Sunglass Hut, LensCrafters, Salmoiraghi & Viganò and GrandVision are part of the EssilorLuxottica family. EssilorLuxottica has approximately 190,000 employees. For more information, please visit www.essilorluxottica.com



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.



Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.



Proud to be **silver sponsors** of Ophthalmology Futures Forums 2023

BRONZE

elios vision

ELIOS Vision, Inc. is a private medical device company focused on the commercialization of ELIOS, a proprietary excimer laser treatment for glaucoma. Our goal is to achieve a leadership position within the glaucoma treatment category with a treatment that is proven safe and effective, 'implant free' and highly adoptable by physicians. The technique is minimally invasive and can be elegantly combined with routine cataract surgery. ELIOS helps address the needs of >80Mn people worldwide affected by glaucoma. ELIOS is approved for use in EU and is currently undergoing clinical trials for use in the US. Visit us online at eliosvision.com

Théa
let's open our eyes

Théa is the leading independent European pharmaceutical group in ophthalmology. Leader and pioneer in preservative-free treatments, Théa is the unique partner of the eye care professionals for it has constantly been innovating to provide them and their patients with answers to unmet eye care needs. Today, Théa's network includes 1,600 collaborators, and its products are available in 75 countries around the world through its 35 affiliates and partners. In 2021, Théa had global revenues of approximately \$773 million. The independent and family-owned and run group, founded from a R&D start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret. www.laboratoires-thea.com/en

GLAUKOS
TRANSFORMING VISION

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease. www.glaukos.com

NEW INNOVATOR

Radiance Therapeutics

Radiance Therapeutics, Ltd. (RadianceTx) is revolutionising the treatment of glaucoma. Intraocular pressure (IOP) reduction by filtration surgery technologies has compelling advantages over nonsurgical treatments. However, bleb management remains challenging because of the high incidence of post-operative scarring. Randomized Controlled Trials from Moorfields Eye Hospital and collaborating institutions, demonstrate that beta therapy significantly reduces postoperative scarring. RadianceTx is addressing this unmet need by developing the RTx-RBS, a next generation Beta Ophthalmic Applicator indicated for episcleral brachytherapy.

Ciliotech
TRANSFORMING GLAUCOMA SURGERY

CILIATECH is developing a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. The company's groundbreaking concept CID (Cilio-scleral Interpositioning Device) is the first implant in the industry to reduce IOP without penetrating the anterior chamber or creating subconjunctival filtration. Clinical trials show IOP is reduced by 39% at 24 months (85% patients drop free, no reoperation needed) and without ECL risk.

AURION
BIOTECH

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells manufactured from a single donor can treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and central corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit www.aurionbiotech.com

Oculis

Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

LensGen
Restoring Youthful Vision

LensGen® pioneered Modular, Shape Changing IOL technology designed to mimic the natural lens and utilize the eye's focusing mechanism to activate a fluid optic that changes shape to increase range of focus while preserving optical quality. The Juvene® Modular, Shape Changing IOL is designed to provide a full range of continuous vision from distance to near with optical quality comparable to monofocal IOLs. Juvene fills the capsule for optimization of refractive and IOL stability and mitigation of PCO. LensGen plans to initiate its IDE pivotal study in the U.S. in Q4/2023.

VIA LASE

ViaLase, Inc. a globally-minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care. With a leadership team that has vast experience developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients, ViaLase looks forward to bringing that expertise and innovation to glaucoma patients worldwide.



An Astellas Company

Hope in sight™

We see a world where vision is preserved.

Pioneering transformational therapies for people with retinal diseases.



ivericbio.com

Copyright © 2023 IVERIC bio, Inc., An Astellas Company.
All rights reserved. US-GA-2300212 06/23

PROGRAMME COMMITTEE

Ike Ahmed | Division Head, Ophthalmology, Trillium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

Jorge Alio | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain.

Gerd Auffarth | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

Francesco Bandello | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

David Chang | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

Steve Charles | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

Paul Chew | Professor of Ophthalmology, National University of Singapore, Singapore.

Jost Jonas | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

Sir Peng Khaw | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

Shigeru Kinoshita | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

Richard Lindstrom | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

Boris Malyugin | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

Ursula Schmidt-Erfurth | Professor & Chair, Medical University of Vienna, Austria

Prof David Spalton | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

Prof Dr Ingeborg Stalmans | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

Paulo Eduardo Stanga | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

José-Alain Sahel | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

Ursula Schmidt-Erfurth | Professor & Chair, Medical University of Vienna, Austria

Chelvin Sng | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

Julian D. Stevens | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

Donald Tan Tiang Hwee | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

Marie-Jose Tassignon | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

Adnan Tufail | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

Tien Yin Wong | Founding Head & Chair Professor, Tsinghua University, Beijing, China.

ADVISORS

Laurent Attias | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

Christopher Brittain | Global Head of Ophthalmology, Genentech, Burlingame, USA.

Arthur Ciociola | Vice President Global Head Regulatory Affairs GDD Ophthalmology, Devices, & Innovation, Novartis Pharma AG, Fort Worth, USA.

Eugene de Juan | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

Tom Dunlap | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

Malvina Eydelman | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

Reza Haque | SVP & Global Head of OIC, Ophthalmic Innovation Center, Santen Santen Pharmaceutical.

Paul Hallen | Vice President & Global Head, Retina, Alcon, Texas, USA.

Jim Mazzo | Executive Chairman, Neurotech.

Naveed Siddiqi | Novo Ventures.

ORGANISING COMMITTEE

Keith Barton | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

Kuldev Singh | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

Lea Pietrolongo | Operational Director, Ophthalmology Futures Forums, UK.



STAAR
SURGICAL